hotspot -WSS

hotspot

author：explore 2025-08-31 01:58:12 - browse：575

Photo illustration based on photograph of The University of Texas MD Anderson Cancer Center in Houston, Texas in 2022 — Photo illustration: STAT; Photo: Adobe

Three years ago, Jamie Lin, an early-career nephrologist at MD Anderson Cancer Center, made findings that could potentially help both save the kidneys of cancer patients and propel her career as a physician-scientist hoping to one day run her own lab. It was a promising start, but that’s when Lin says one of the Texas institute’s most powerful researchers interfered.

Lin alleges in a lawsuit that prominent oncologist Padmanee Sharma derailed the publication of papers based on Lin’s work, threatened to undermine her fledgling career, and made defamatory comments about her in retaliation for resisting making Sharma an author on a paper and saying the senior researcher had made no substantial contribution to it.

“Having this and another paper taken — what would’ve been important papers for my career,” Lin told STAT in an interview. “I’m sure that my career in research has just fallen off a cliff.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Moderna says combo Covid

leisure time

WSS

Deposition: Sackler embraced plan to conceal OxyContin’s strength

New report analyzes digital physical therapy solutions' effectiveness

5 takeaways from STAT's examination of Zynex Medical

What STAT readers think about the FDA and patient advocacy

5 takeaways from STAT's examination of Zynex Medical

Christmas in the PICU brings some surprising joy

hotspot

hotspot

focus

Novavax promises a turnaround & Lilly roils the obesity market

Medicare drug price negotiation hasn't dried up venture capital

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

How faith leaders like me can help address America's obesity epidemic

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Grail spinoff by Illumina should end disastrous merger attempt

State Dept. review finds Biden bears some blame for Afghanistan failures

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

In Memoriam: Notable people who died in 2023

SEC charges former device maker CEO with $41 million fraud

explore

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Keeping primary care docs in field isn't impossible, says AAFP CEO

Virtual care provider acquires bankrupt Pear's prescription apps

HCA sued by state AG for quality issues at Mission Health

Coercive sterilizations revealed by STAT prompt outrage

explore

leisure time

knowledge

hotspot